drugset / Trial / NCT00078039

Trial Evaluating Three Fixed Dosages of Paliperidone Extended-Release (ER) Tablets and Olanzapine in the Treatment of Patients With Schizophrenia

NCT00078039

RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of the double blind phase of this study is to evaluate the efficacy and safety of 3 fixed dosages of paliperidone ER (6, 9, and 12 mg/day) compared with placebo in adult patients with schizophrenia.

Timeline

Start
2004-03
Primary completion
Completion
2005-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Paliperidone Unknown 3 mg Oral
Subject Paliperidone Unknown 6 mg Oral
Subject Paliperidone Unknown 9 mg Oral
Subject Paliperidone Unknown 12 mg Oral

Indications